Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21112995 | 0.91 | TTR (0.53) | TTRTDP1ALDH1A1KMT2AXDH | |
| SCHEMBL24137716 | 0.91 | TTR (0.53) | TTRTDP1ALDH1A1KMT2AXDH | |
| SCHEMBL20873306 | 0.88 | TTR (0.44) | TTRTDP1ALDH1A1KMT2AXDH | |
| SCHEMBL21112942 | 0.87 | TDP1 (0.56) | TTRTDP1ALDH1A1KMT2AXDH | |
| SCHEMBL21112893 | 0.87 | SMN1; SMN2 (0.45) | TDP1ALDH1A1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL21112880 | 0.86 | MEN1 (0.43) | TDP1ALDH1A1KMT2ANPC1MAPT | |
| SCHEMBL20873307 | 0.80 | XDH (0.57) | TTRTDP1ALDH1A1KMT2AXDH | |
| SCHEMBL21112859 | 0.79 | SRD5A2 (0.38) | TDP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL23488434 | 0.79 | XDH (0.49) | TDP1ALDH1A1KMT2AXDHNPC1 | |
| SCHEMBL24145071 | 0.78 | TTR (0.49) | TTRTDP1ALDH1A1XDHNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885TDP1 4001/4885ALDH1A1 1514/4885 |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885TDP1 4001/4885ALDH1A1 1514/4885 |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885TDP1 4001/4885ALDH1A1 1514/4885 |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885TDP1 4001/4885ALDH1A1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.